Browse by Poster Number

1001

Identification of novel targets that upregulate CD20 expression in rituximab-resistant cells with the use of genome-wide CRISPR screening

Clinical Challenges in CLL

Favorite

1002

m6A-modified circTET2 interacting with HNRNPC regulates fatty acid oxidation to promote the proliferation of chronic lymphocytic leukemia

Pathogenesis of CLL

Favorite

1003

Refining the phenotypic and functional intraclonal complexity in chronic lymphocytic leukemia B cells uncovers a discrepancy between surface membrane IG levels and time since birth supporting the requirement for multifactorial activation and different subclonal sensitivities to treatment.

Pathogenesis of CLL

Favorite

1004

The PKCβ inhibitor MS-553 displays preclinical efficacy in BTK inhibitor resistant Chronic Lymphocytic Leukemia

Clinical Challenges in CLL

Favorite

1005

Toll-like receptor 9 signalling in CLL: a resistance mechanism to B-cell receptor-targeted treatments, and a potential tool for therapeutic stratification.

Therapy of CLL

Favorite

1006

Transcription factor FoxO1 Mediates Adaptive Increase in Akt Activity and Cell Survival During BCR Inhibitor Therapy in CLL

Clinical Challenges in CLL

Favorite

1007

XPO1 mutations identify early stage CLL characterized by shorter time to first treatment and enhanced BCR signaling

Pathogenesis of CLL

Favorite

1008

XPO1 inhibitor Selinexor induces heme oxygenase-1 mediated p53-dependent ferroptosis in chronic lymphocytic leukemia

Therapy of CLL

Favorite

1009

IMMUNOGENETICS AND ANTIGEN REACTIVITY PROFILING CONTRIBUTE TO UNRAVELLING THE ONTOGENY OF CLL STEREOTYPED SUBSET #4

Pathogenesis of CLL

Favorite

1010

The interplay between BcR signaling and the p53 pathway upon DNA damage in primary CLL cells

Pathogenesis of CLL

Favorite

1011

In-depth molecular analysis using a multi-gene lymphoma NGS panel in lymphomas with lymphoplasmacytic differentiation may provide more precise diagnosis, differentiation of entities and may optimize rational treatment allocations

Pathogenesis of CLL

Favorite

1012

High-dimensional Single-cell Characterisation of the Chronic Lymphocytic Leukaemia Tumour Microenvironment using Imaging Mass Cytometry

Pathogenesis of CLL

Favorite

1013

The role of artificial intelligence in differential diagnosis and prognostic significance of Small B-cell lymphoma

Clinical Challenges in CLL

Favorite

1014

Clonal architecture and single-cell transcriptome landscape in Richter’s syndrome

Clinical Challenges in CLL

Favorite

1015

Coupled effect of a miR-155 deficiency and hypoxia conditions leads to the upregulation of SLC2A1 (GLUT1), SLC2A3 (GLUT3) and EGLN1 genes in the leukemic B-cells

Pathogenesis of CLL

Favorite

1016

DEFACTINIB AFFECTS CHRONIC LYMPHOCYTIC LEUKEMIA CELL SURVIVAL WITH ADDITIVE EFFECT IN COMBINATION WITH BTK INHIBITORS

Clinical Challenges in CLL

Favorite

1017

NOTCH pathway mutation contributes to inferior prognosis in HBV-infected chronic lymphocytic leukemia

Pathogenesis of CLL

Favorite

1018

Fatty Acid Metabolism Fingerprints Predict Prognosis and Regulate Immunophenotype in Chronic Lymphocytic Leukemia

Pathogenesis of CLL

Favorite

1019

Chemokine receptor and adhesion molecule profile on B-cell chronic lymphocytic leukemia (B-CLL) lymphocytes in different lymphoid compartments and changes during BTK inhibitor therapy

Pathogenesis of CLL

Favorite

1020

The mechanical properties of CLL cells are linked to the actin cytoskeleton and are target of BTK inhibitors

Therapy of CLL

Favorite

1021

Transcriptional correlation analysis of the CD180/MD-1 complex and toll-like receptors and signaling lymphocyte activation family receptors in chronic lymphocytic leukemia.

Pathogenesis of CLL

Favorite

1022

FOXO4 is required for the promotion of CLL growth and survival

Pathogenesis of CLL

Favorite

1023

Targeting NF-κB-inducing kinase (NIK) in chronic lymphocytic leukaemia

Therapy of CLL

Favorite

1024

Impaired mitochondrial metabolism drives T-cell dysfunction in chronic lymphocytic leukemia

Pathogenesis of CLL

Favorite

1025

Curcumin enhances ibrutinib induced killing effect against TP53-mutated Chronic Lymphocytic Leukemia cells in vitro

Clinical Challenges in CLL

Favorite

1026

Targeting the pro-inflammatory protein S100-A9 in Chronic Lymphocytic Leukemia

Pathogenesis of CLL

Favorite

1027

B cell receptor-mediated signals modulate rapid FOXO1 upregulation in chronic lymphocytic leukaemia: a role for deubiquitinate proteins?

Pathogenesis of CLL

Favorite

1028

Peripheral Blood CXCR4hiCD5hi Chronic Lymphocytic Leukaemia Cells are Primed for Returning to the Lymph Nodes for further Activation and Proliferation

Pathogenesis of CLL

Favorite

1029

Deubiquitinase PSMD14 Promotes Progression of Chronic Lymphocytic Leukemia by Stabilizing CSDE1

Pathogenesis of CLL

Favorite

1030

Immunophenotypic Characterization of Richter Syndrome Diffuse Large B-Cell Lymphoma Type and Comparison with the Original Chronic Lymphocytic Leukemia

Clinical Challenges in CLL

Favorite

1031

Sex Bias in Mutational Landscape of Chronic Lymphocytic Leukemia: Analysis of Clinical Sequencing Data

Pathogenesis of CLL

Favorite

1032

Clonal Space Assessment in Chronic Lymphocytic Leukemia Using an Unbiased NGS Approach

Clinical Challenges in CLL

Favorite

1033

Single-Cell Transcriptome Profiling Reveals Neoplastic Effects of Exosomal S100A4 in Chronic Lymphocytic Leukemia

Pathogenesis of CLL

Favorite

1034

Venetoclax resistance induced by activated T cells can be counteracted by sphingosine kinase inhibitors in chronic lymphocytic leukemia

Clinical Challenges in CLL

Favorite

1035

ENPP2 mediates lipid metabolism and tumorigenesis in chronic lymphocytic leukemia through AMPK signaling pathway

Pathogenesis of CLL

Favorite

1036

Chronic lymphocytic leukemia extracellular vesicles induce the differentiation of monocytes into nurse-like cells

Pathogenesis of CLL

Favorite

1037

Activation of S100-A9/EMMPRIN axis triggers survival/proliferation pathways in leukemic cells. A novel target for chronic lymphocytic leukemia

Pathogenesis of CLL

Favorite

1038

Inhibition of G protein-coupled receptor kinase 2 (GRK2) as a strategy to modulate leukemic cell homing and activation in CLL

Pathogenesis of CLL

Favorite

1039

The proto-oncogene TCL1A deregulates cell cycle and genomic stability in CLL

Pathogenesis of CLL

Favorite

1040

Exploring the impact of germline ATM mutations in cancer susceptibility and inheritance in chronic lymphocytic leukemia

Pathogenesis of CLL

Favorite

1041

Anti-FcμR Antibody Drug Conjugate as a Potential Therapeutic Agent for the Treatment of Chronic Lymphocytic Leukemia

Therapy of CLL

Favorite

1042

LOSS OF IκBε ACCELERATES DISEASE DEVELOPMENT IN CHRONIC LYMPHOCYTIC LEUKEMIA

Pathogenesis of CLL

Favorite

1043

Regulation of the NF-kB pathway by NEDDylation in chronic lymphocytic leukemia: Beyond IkB

Pathogenesis of CLL

Favorite

1044

T cells from chronic lymphocytic leukemia patients are not exhausted but show signs of senescence, providing alternative clues for improvement

Pathogenesis of CLL

Favorite

1045

LYN kinase programs stromal fibroblasts to facilitate leukemic survival via regulation of c-JUN and THBS1

Pathogenesis of CLL

Favorite

1046

Unveiling the Role of Siglec-6 in Regulating B Cell Functions: Implications for Chronic Lymphocytic Leukemia Therapeutics

Pathogenesis of CLL

Favorite

1047

Prognosis Analysis and Validation of Fatty Acid Metabolism-Related Signature in Chronic lymphocytic leukemia

Pathogenesis of CLL

Favorite

1048

SH2-Flow: A Multiplex Single Cell Phosphotyrosine Profiling Tool for B-cell Malignancies

Pathogenesis of CLL

Favorite

1049

Impact of T-cell co-stimulatory molecule CLECL1 expressing CLL cells on CLL disease progression and transformation to Richter's syndrome

Pathogenesis of CLL

Favorite

1050

NX-2127 and NX-5948, two clinical stage cereblon-recruiting BTK degraders, facilitate T-cell functionality in CLL

Pathogenesis of CLL

Favorite

1051

Increased susceptibility to Streptococcus pneumoniae pulmonary infection in the Eµ-TCL1 adoptive transfer mouse model of CLL

Pathogenesis of CLL

Favorite

1052

PI3K inhibitor-resistant B-cell lymphomas show distinct functional phenotypes characterized by sensitivity to Bcl-2- or proteasome-inhibition

Clinical Challenges in CLL

Favorite

1053

Explainable Machine Learning to Identify Chronic Lymphocytic Leukemia Based on Gut Microbiome Data

Past, Present, and Future in CLL

Favorite

1054

The RNA-binding protein Musashi2 is regulated by NOTCH1/KLF4 pathway and support tumor survival keeping CLL cells in proliferative niches during disease progression

Pathogenesis of CLL

Favorite

1055

Single-cell transcriptomic analysis of CLL cells at ibrutinib plus venetoclax relapse and targeting using BCL-2/BCL-xL PROTACs PZ18753b and WH25244

Clinical Challenges in CLL

Favorite

1056

LYN kinase and its regulator CSK as key players in CLL-supporting macrophages

Pathogenesis of CLL

Favorite

1057

Combining CD19 CAR T cells with T cell-engaging bispecific antibody treatment enhances efficacy in murine models of CLL and ex vivo patient cultures

Pathogenesis of CLL

Favorite

1058

T-cell Transcriptional and Mitochondrial Fitness Reprogramming in CLL Using PI3Kδ Inhibitors

Pathogenesis of CLL

Favorite

1059

Lisaftoclax (APG-2575) is a novel BCL-2 inhibitor with robust antitumor activity in preclinical models of hematologic malignancy

Therapy of CLL

Favorite

1101

Association between hypertension and overall survival in chronic lymphocytic leukemia

Clinical Challenges in CLL

Favorite

1102

Integrating Multi-Omics to Reveal the Heterogeneous Clonal Evolutionary Characteristics in CLL Patients with Zanubrutinib Resistance

Clinical Challenges in CLL

Favorite

1103

Single-cell RNA sequencing Reveals the Spatial Heterogeneity in BTKi-Resistant Richter Transformation Patients

Clinical Challenges in CLL

Favorite

1104

Non-Hematological Autoimmune Disorders are frequent in CLL, but are they clinically related? Data from a Single-center Real-Life Cohort

Clinical Challenges in CLL

Favorite

1105

SAFETY AND EFFECTIVENESS IN CLL PATIENTS TREATED WITH VENETOCLAX MONOTHERAPY IN AUSTRIA, GERMANY, AND SWITZERLAND - LONG TERM FOLLOW UP DATA

Therapy of CLL

Favorite

1106

Clinical Relevance of the Recommended Intensive Laboratory Monitoring during the Standard Ramp-up at Time of Venetoclax Initiation for CLL: A Real-World Experience

Therapy of CLL

Favorite

1107

Mechanisms of differential response to BTKi targeted therapy in patients with chronic lymphocytic leukemia

Clinical Challenges in CLL

Favorite

1108

Uncovering the immune-related challenges facing people with chronic lymphocytic leukaemia

Past, Present, and Future in CLL

Favorite

1109

Real world treatment patterns, reasons for discontinuation, and survival outcomes among patients with chronic lymphocytic leukemia/ small lymphocytic lymphoma (CLL/SLL) receiving second or later lines of therapy in a contemporary population treated in the United States

Clinical Challenges in CLL

Favorite

1110

Systematic literature review (SLR) of treatments and outcomes in patients with relapsed or refractory (R/R) chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) previously treated with Bruton tyrosine kinase inhibitors (BTKi) and venetoclax

Clinical Challenges in CLL

Favorite

1111

Immune-profiling of ibrutinib-treated CLL patients revealed TMBIM6 as a potential target for CLL and its high expression as an independent variable associated with poor prognosis

Pathogenesis of CLL

Favorite

1112

Immunophenotyping of Chronic Lymphocytic Leukemia in Yemen.

Past, Present, and Future in CLL

Favorite

1113

Pericardial effusion in patients with chronic lymphocytic leukemia treated with Bruton's tyrosine kinase inhibitors

Therapy of CLL

Favorite

1114

Pharmacokinetics of idelalisib and outcomes

Therapy of CLL

Favorite

1115

Venetoclax Consolidation after BTKi Based Therapy for Patients with CLL

Therapy of CLL

Favorite

1116

SAFETY PROFILE IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA UNDERGOING TREATMENT WITH 1ST AND 2ND GENERATION BRUTON TYROSINE KINASE INHIBITORS: MULTICENTRIC REAL-WORLD EXPERIENCE

Therapy of CLL

Favorite

1117

EVOLUTION IN THE FRONTLINE TREATMENT OF PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA: EXPERIENCE FROM ONE EUROPEAN CENTER

Past, Present, and Future in CLL

Favorite

1118

Past, Present, and Future in CLL

Favorite

1119

Treatment Strategies and Outcomes for Double Refractory chronic lymphocytic leukemia; A single center experience

Clinical Challenges in CLL

Favorite

1120

Single-cell RNA-seq analysis reveals distinct tumor and immunosuppressive T cell phenotypes in CLL patients treated with ibrutinib.

Pathogenesis of CLL

Favorite

1121

Safety of concomitant delivery of radiotherapy for second primary malignancy in patients with chronic lymphocytic leukemia treated with continuous novel agents

Clinical Challenges in CLL

Favorite

1122

Treatment Patterns and Outcomes of Patients with TP53-Mutated Chronic Lymphocytic Leukemia

Clinical Challenges in CLL

Favorite

1123

Anti-CD19 Chimeric Antigen Receptor T-cell therapy for Richter’s Transformation: A Multicenter Retrospective Study

Clinical Challenges in CLL

Favorite

1124

Efficacy and toxicity of ibrutinib in CLL - Croatian experience. A non-interventional, real world study of KroHem

Therapy of CLL

Favorite

1125

Frequent monitoring in chronic lymphocytic leukemia clinical trials: what is the true value?

Clinical Challenges in CLL

Favorite

1126

Significance of sIL-2R and LD in predicting time to first treatment in Japanese CLL patients with early asymptomatic disease.

Clinical Challenges in CLL

Favorite

1127

Real-world treatment patterns, discontinuation and clinical outcomes in patients with B-cell lymphoproliferative diseases treated with BTK inhibitors in China

Therapy of CLL

Favorite

1128

Single-center study of COVID-19 infection in patients with chronic lymphocytic leukemia

Past, Present, and Future in CLL

Favorite

1129

Incidence and clinical correlates of non-immune cytopenia at diagnosis of chronic lymphocytic leukemia

Past, Present, and Future in CLL

Favorite

1130

Vertebral fractures in patients with B-cell chronic lymphocytic leukemia before and after ibrutinib treatment

Clinical Challenges in CLL

Favorite

1131

Performance of a novel 8-color flow cytometry panel in the detection of minimal residual disease assessment of chronic lymphocytic leukemia

Clinical Challenges in CLL

Favorite

1132

Very low COVID mortality and hospitalization rates in CLL and MBL with repeated vaccination to maximum antibody response

Past, Present, and Future in CLL

Favorite

1133

COVID-19 infection in chronic lymphocytic leukemia (CLL) patients treated with venetoclax: a Danish single-center experience

Clinical Challenges in CLL

Favorite

1134

High deletion burden identified by whole genome sequencing is associated with enhanced risk in del17p CLL patients

Pathogenesis of CLL

Favorite

1135

Predictive modeling of treatment outcomes in chronic lymphocytic leukemia based on functional profiles at baseline

Clinical Challenges in CLL

Favorite

1136

Serum Monoclonal Immunoglobulin Predicts Inferior Prognosis in Patients Treated for Chronic Lymphocytic Leukemia

Past, Present, and Future in CLL

Favorite

1137

Efficacy of Immune Checkpoint Inhibitors for the Treatment of Advanced Melanoma (AM) in Patients with Concomitant Chronic Lymphocytic Leukemia (CLL)

Clinical Challenges in CLL

Favorite

1138

Low dose rituximab efficiently clears circulating CLL cells and maintains sensitivity to antibody dependent cellular cytotoxicity (ADCP)

Therapy of CLL

Favorite

1139

Initial anti-CD20 monoclonal antibody therapy in CLL quickly induces cytokine release syndrome with first dose infusion reaction correlating only with high IL-6, IL-8 and IP-10

Therapy of CLL

Favorite

1140

Pregnancy course of 10 women diagnosed with Chronic Lymphocytic Leukemia

Clinical Challenges in CLL

Favorite

1141

Reduced predictive value of elevated Beta-2-microglobulin plasma levels on time to first treatment in newly diagnosed CLL patients with compromised kidney function

Past, Present, and Future in CLL

Favorite

1142

Treatment of symptomatic paraneoplastic fluidothorax in CLL with novel agents: a single-center case series.

Therapy of CLL

Favorite

1143

The Economic Benefits of Time Off Treatment: Real-World HRU, Costs, and Subsequent Treatment with Fixed Duration Venetoclax among Patients with Chronic Lymphocytic Leukemia

Past, Present, and Future in CLL

Favorite

1144

Patients with unmutated IgHV_1-69; 1-02; 3-30; 4-39 and high expression of AID enzyme need earlier treatment.

Pathogenesis of CLL

Favorite

1145

The role of 18F-FDG PET-CT in Richter Transformation and accelerated CLL

Clinical Challenges in CLL

Favorite

1146

Implementing the data-driven CLL-TIM algorithm into an EPIC-based EHR: proof of concept for automated decision support models

Past, Present, and Future in CLL

Favorite

1147

Global Perspectives through multi stakeholder mapping of lived experience with CLL – insights to improve equity, services, and unmet need

Clinical Challenges in CLL

Favorite

1148

Time to treatment initiation in 17p-deleted Chronic Lymphocytic Leukemia has no influence on overall survival

Therapy of CLL

Favorite

1149

Ibrutinib induces cardiac arrhythmia by targeting CaV1.2 calcium channel

Pathogenesis of CLL

Favorite

1150

Past informs the future: outcomes post allogeneic stem cell transplantation in high risk chronic lymphocytic leukaemia (CLL)

Past, Present, and Future in CLL

Favorite

1151

The Impact of BTK Inhibitors on COVID-19 Outcomes in Patients with Chronic Lymphocytic Leukemia: A real-world study in the Omicron wave

Therapy of CLL

Favorite

1152

Optical genome mapping and fluorescence in situ hybridization is the best combination to identify genomic complexity and TP53 deletions in CLL patients

Pathogenesis of CLL

Favorite

1153

SWITCHING FROM COVALENT BTKI TO BCL2i IS ASSOCIATED WITH IMPROVED CLINICAL OUTCOMES COMPARED TO SWITCHING TO A DIFFERENT COVALENT BTKI IN PATIENTS WITH CLL/SLL TREATED IN THE REAL-WORLD SETTING

Therapy of CLL

Favorite

1154

Impaired long-term antibody persistence after primary immunization with pneumococcal vaccines in patients with chronic lymphocytic leukemia compared to immunocompetent controls

Past, Present, and Future in CLL

Favorite

1155

Loss of AID exacerbates the malignant progression of CLL

Pathogenesis of CLL

Favorite

1156

Real-world Effectiveness and Safety of Tixagevimab/Cilgavimab Lower Dosage Regimen in Pre-Exposure Prophylaxis in Patients Undergoing Treatment for Chronic Lymphocytic Leukemia

Past, Present, and Future in CLL

Favorite

1157

Significance of TP53 aberrations in context of other pathogenic sequence variants in patients with chronic lymphocytic leukemia in the era of targeted therapy

Clinical Challenges in CLL

Favorite

1158

A retrospective study evaluating the sequence of BTKi and venetoclax, with a focus on toxicity

Therapy of CLL

Favorite

1160

Clinical outcomes in patients with chronic lymphocytic leukemia (CLL) treated with venetoclax-based regimens

Clinical Challenges in CLL

Favorite

1161

ZMYM3 Mutations Dysregulate Histone Acetylation and Impact the Outcome Of Chronic Lymphocytic Leukemia Patients

Pathogenesis of CLL

Favorite

1162

Time-limited venetoclax-rituximab is effective for patients with Bruton tyrosine kinase exposed chronic lymphocytic leukaemia, but durable treatment-free remissions are uncommon

Therapy of CLL

Favorite

1163

Sensitive monitoring of sequential targeted therapy resistance in relapsed/therapy refractory chronic lymphocytic leukemia

Clinical Challenges in CLL

Favorite

1164

Mutations and translocations associated with venetoclax resistance in chronic lymphocytic leukemia (CLL)

Clinical Challenges in CLL

Favorite

1201

Impact of COVID-19 in patients with Chronic Lymphocytic Leukemia treated with venetoclax: a possible role of the association to anti-CD20 antibody? A multicentre SEIFEM study.

Past, Present, and Future in CLL

Favorite

1202

T cell type abundance and gene expression patterns in the context of clinical progression of treatment-naïve CLL/MBL patients from the OxPLoreD study

Pathogenesis of CLL

Favorite

1203

Chronic obstructive pulmonary disease and previous infections have impact on infectious complications in patients with Chronic Lymphocytic Leukemia treated with venetoclax: a multicentre SEIFEM study.

Past, Present, and Future in CLL

Favorite

1204

Real-World Characteristics and Outcomes of Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Treated With Long-Term Ibrutinib: Results From the Prospective, Observational informCLL Registry

Clinical Challenges in CLL

Favorite

1205

Rituximab Maintenance after Chemoimmunotherapy Induction in 1st and 2nd Line Improves Progression Free Survival: Long Term Follow up of the International Randomized AGMT-CLL8/a Mabtenance Trial

Therapy of CLL

Favorite

1206

First-in-human open-label study of lisaftoclax (APG-2575), a novel BCL-2 inhibitor, in patients with relapsed/refractory chronic lymphocytic leukemia and other hematologic malignancies

Clinical Challenges in CLL

Favorite

1207

A matching-adjusted indirect comparison of ELEVATE-TN versus SEQUOIA: acalabrutinib with and without obinutuzumab versus zanubrutinib in treatment-naïve chronic lymphocytic leukemia

Therapy of CLL

Favorite

1208

The HEALTH4CLL study: optimization of behavioral interventions for patients with chronic lymphocytic leukemia

Clinical Challenges in CLL

Favorite

1209

Ibrutinib plus fludarabine, cyclophosphamide and rituximab (iFCR) as initial treatment in chronic lymphocytic leukemia/ small lymphocytic leukemia with or without TP53 aberrations: A prospective real-world study in Chinese cohort

Therapy of CLL

Favorite

1210

A Phase II study of intermittent duvelisib dosing in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)

Therapy of CLL

Favorite

1211

Venetoclax as an Alternative and Effective Treatment in Central Nervous System Involvement of Chronic Lymphocytic Leukemia: Monocentric Experience

Past, Present, and Future in CLL

Favorite

1212

Targeted agents in chronic lymphocytic leukemia (CLL): Data on outcomes and subsequent therapies of patients observed within the German CLL Study Group (GCLLSG) registry

Therapy of CLL

Favorite

1213

An examination of health literacy amongst patients with Chronic Lymphocytic Leukemia- A study from The Lymphoma Coalition Global Patient Survey 2022.

Past, Present, and Future in CLL

Favorite

1214

An Investigation into the Differences between Western and Chinese population with Chronic Lymphocytic Leukemia

Therapy of CLL

Favorite

1215

Unveiling the Spectrum of Genetic Alterations in Relapsed/Refractory CLL Patients on Targeted Inhibitors: A Prospective Unicentric Study

Pathogenesis of CLL

Favorite

1216

Characterizing Specificities of Chronic Lymphoid Leukemia Harboring a BCL2 Rearrangement, an update from the FILO group

Pathogenesis of CLL

Favorite

1217

Evolution of natural history and prolongation of overall survival in patients with chronic lymphocytic leukemia: analysis of a long-term follow-up of an unselected cohort in the Hradec Králové district, Czech Republic.

Past, Present, and Future in CLL

Favorite

1218

Lenalidomide Consolidation Improves Progression Free Survival in Patients with Chronic Lymphocytic Leukemia Following Initial FCR Chemotherapy - Final Analysis of CLL6 Residuum Study of the Australian Leukaemia and Lymphoma Group (ALLG) and the French Innovative Leukemia Organization (FILO)

Therapy of CLL

Favorite

1219

The evolution of treatments and outcome of patients with chronic lymphocytic leukemia treated at Fondazione Policlinico Universitario Agostino Gemelli IRCCS: a monocentric experience of the Last 30 Years.

Past, Present, and Future in CLL

Favorite

1220

Longitudinal review of cardiac events with acalabrutinib in the treatment of chronic lymphocytic leukemia (CLL) using data from 3 phase 3 randomized controlled trials (RCTs)

Therapy of CLL

Favorite

1221

Occurrence and Evolution of Autoimmune Cytopenias in Chronic Lymphocytic Leukemia Patients treated with Venetoclax: a study of the French Innovative Leukemia Organization (FILO).

Past, Present, and Future in CLL

Favorite

1222

KINETICS OF LYMPHOCYTOSIS DURING BTK COVALENT INHIBITORS IN TREATMENT NAÏVE CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS. AN ITALIAN MULTICENTER EXPERIENCE OF REAL LIFE.

Therapy of CLL

Favorite

1223

Anti-CD19 CAR T-cell therapy for patients with Richter syndrome: A LYSA Study from the DESCAR-T Registry

Therapy of CLL

Favorite

1224

Incidence of arrhythmia in chronic lymphocytic leukemia (CLL) patients treated with ibrutinib: a real-world retrospective analysis from two Italian centers.

Past, Present, and Future in CLL

Favorite

1225

Real-world evidence on venetoclax in chronic lymphocytic leukemia: The KROHEM (Croatian cooperative group for hematological diseases) experience

Past, Present, and Future in CLL

Favorite

1226

Outcomes of Tixagevimab/cilgavimab pre-exposure prophylaxis in Chronic lymphocytic leukemia patients- a single center experience

Clinical Challenges in CLL

Favorite

1227

Concomitant use of venetoclax 100 mg and ketoconazole to treat CLL in a public center in Brazil

Therapy of CLL

Favorite

1228

Single center report on cohort of patients relapsed on Bruton Tyrosine Kinase inhibitors (BTKi)

Clinical Challenges in CLL

Favorite

1229

A Study of Frontline Therapy in Adults Aged 80+ Years with Chronic Lymphocytic Leukemia (CLL)

Therapy of CLL

Favorite

2001

Changes in immune cell numbers and profile during long-term zanubrutinib treatment in treatment-naïve and relapsed/refractory patients with chronic lymphocytic leukemia

Therapy of CLL

Favorite

2002

Final 7-year Follow Up and Retreatment Substudy Analysis of MURANO: Venetoclax-Rituximab-Treated Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia

Clinical Challenges in CLL

Favorite

2003

Genomic Evolution and Resistance to Pirtobrutinib in Covalent BTK-Inhibitor Pre-treated Chronic Lymphocytic Leukemia Patients: Results from the Phase I/II BRUIN Study

Therapy of CLL

Favorite

2004

Lisocabtagene maraleucel (liso-cel) in R/R chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL): primary analysis of TRANSCEND CLL 004

Clinical Challenges in CLL

Favorite

2005

A phase 1 study evaluating PRT2527, a potent and highly selective CDK9 inhibitor, in patients with select relapsed/refractory B-cell malignancies

Clinical Challenges in CLL

Favorite

2006

Impact of nucleotide metabolism on CLL B-cell pathobiology and CLL disease progression

Pathogenesis of CLL

Favorite

2007

Real-World Duration of Venetoclax Treatment for Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma

Past, Present, and Future in CLL

Favorite

2008

BRUIN CLL-314: A phase 3, open-label, randomized study of pirtobrutinib versus ibrutinib in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (trial in progress)

Therapy of CLL

Favorite

2009

A phase 2 study of zanubrutinib in previously treated B-cell malignancies intolerant to ibrutinib and/or acalabrutinib: preliminary results for patients with CLL/SLL

Therapy of CLL

Favorite

2010

Zanubrutinib vs bendamustine + rituximab (BR) in patients with treatment-naive chronic lymphocytic leukemia/small lymphocytic lymphoma: extended follow-up of the SEQUOIA study

Therapy of CLL

Favorite

2011

Long-term Safety with ≥12 Months of Pirtobrutinib in Relapsed/Refractory (R/R) B-Cell Malignancies

Therapy of CLL

Favorite

2012

Matching-Adjusted Indirect Comparison of Pirtobrutinib vs Venetoclax Continuous Monotherapy in Patients with Relapsed/Refractory CLL Previously Treated with a Covalent BTK Inhibitor

Therapy of CLL

Favorite

2013

Zanubrutinib vs ibrutinib in relapsed/refractory chronic lymphocytic leukemia and small lymphocytic lymphoma (R/R CLL/SLL): impact on health-related quality of life (HRQoL)

Therapy of CLL

Favorite

2014

Characterization of the safety/tolerability profile of zanubrutinib and comparison with the profile of ibrutinib in patients with B-cell malignancies: post hoc analysis of a large clinical trial safety database

Therapy of CLL

Favorite

2015

VENETOCLAX RETREATMENT AFTER MRD-GUIDED VENETOCLAX +/- IBRUTINIB: THE IMPROVE STUDY COHORT

Therapy of CLL

Favorite

2016

Long-term follow-up of multicenter phase II trial of zanubrutinib, obinutuzumab, and venetoclax (BOVen) in previously untreated patients with chronic lymphocytic leukemia: Impact of early MRD kinetics on posttreatment outcomes

Therapy of CLL

Favorite

2017

Venetoclax-Obinutuzumab for previously untreated chronic lymphocytic leukemia: 6-year results of the randomized CLL14 study

Therapy of CLL

Favorite

2018

Over-Time Monitoring of CXCR4dim/CD5bright Proliferative Fraction Anticipates Relapse In Ibrutinib-Treated CLL : a reservoir for BTK mutations?

Clinical Challenges in CLL

Favorite

2019

Covalent menin inhibitor, BMF-219, impacts key gene signatures and molecular pathways in Chronic Lymphocytic Leukemia patient-derived models

Therapy of CLL

Favorite

2020

NX-5948 and NX-2127 potently degrade a broad array of clinically-relevant BTK mutants that display resistance to inhibitors and other BTK degraders

Clinical Challenges in CLL

Favorite

2021

Past, Present, and Future in CLL

Favorite

2022

Prolonged treatment with ibrutinib modulates phenotypic and functional features of immune cell compartments in chronic lymphocytic leukemia

Therapy of CLL

Favorite

2023

Del8p and TNFRSF10B loss are associated with a poor prognosis and resistance to fludarabine in chronic lymphocytic leukemia

Pathogenesis of CLL

Favorite

2024

Phase 1/2 Study of Zilovertamab and Ibrutinib: Durable responses suggest a novel mechanism for synthetic lethality in TP53 aberrant disease.

Clinical Challenges in CLL

Favorite

2025

Real-world dosing patterns and outcomes in patients with chronic lymphocytic leukemia patients with or without dose adjustment of first-line ibrutinib

Clinical Challenges in CLL

Favorite

2026

Real-world treatment outcomes in patients with chronic lymphocytic leukemia or small lymphocytic lymphoma who were treated with first-line single-agent ibrutinib vs chemoimmunotherapy

Clinical Challenges in CLL

Favorite

2027

Real-world assessment of dosing patterns and treatment outcomes in patients with chronic lymphocytic leukemia who initiated first-line single-agent ibrutinib in an integrated claims-based database

Clinical Challenges in CLL

Favorite

2028

Genomic Alterations and Outcomes with Fixed-duration Ibrutinib + Venetoclax: Results from the Phase 3 GLOW Study in Patients with Previously Untreated CLL

Therapy of CLL

Favorite

3001

Sequencing of circulating tumour DNA reveals additional driver mutations in Richter Transformation

Clinical Challenges in CLL

Favorite

3002

Zanubrutinib and venetoclax as initial therapy for CLL with obinutuzumab triplet consolidation in patients with minimal residual disease positivity (BruVenG)

Therapy of CLL

Favorite

3003

COVALENT-101: Phase I Study of BMF-219, a Covalent Menin Inhibitor, in Adult Patients With AML, ALL (With KMT2A/ MLL1r, NPM1 Mutations), DLBCL, MM, and CLL/SLL (NCT05153330)

Therapy of CLL

Favorite

3004

A Phase 2 Study of Minimal Residual Disease-Guided, Time-Limited, First-Line Therapy of Chronic Lymphocytic Leukemia with Pirtobrutinib and Venetoclax (MIRACLE)

Therapy of CLL

Favorite

3005

BRUIN CLL-322: A phase 3 open-label, randomized study of fixed duration pirtobrutinib plus venetoclax and rituximab versus venetoclax and rituximab in previously treated chronic lymphocytic leukemia/small lymphocytic lymphoma (trial in progress)

Therapy of CLL

Favorite

3006

High-risk International Prognostic Score for early asymptomatic CLL (IPS-E) identifies chronic lymphocytic leukaemia at risk of progression to treatment in the OXPLORED study, a prospective observational study for early lymphoproliferative disease

Past, Present, and Future in CLL

Favorite

3007

Randomized, Phase III Study of Early Intervention with Venetoclax and Obinutuzumab (VO) versus Delayed Therapy with VO in Newly Diagnosed Asymptomatic High-Risk Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL): EVOLVE CLL/SLL Study (SWOG S1925; NCT#04269902)

Therapy of CLL

Favorite

3008

An ongoing first-in-human phase 1 trial of NX-5948, an oral Bruton’s tyrosine kinase (BTK) degrader, in patients with relapsed/refractory B cell malignancies, including chronic lymphocytic leukemia (CLL)

Therapy of CLL

Favorite

3009

Orelabrutinib combined with bendamustine and obinutuzumab as the first-line treatment for chronic lymphocytic leukemia/small lymphocytic leukemia: a phase II multicenter exploratory study

Therapy of CLL

Favorite

4001

Chronic lymphocytic leukemia patient-derived xenografts recapitulate clonal evolution to Richter transformation

Pathogenesis of CLL

Favorite

4002

Longitudinal CITE-Seq analyses of the peripheral blood identify transcriptomic signatures associated with progression and transformation under targeted therapy

Pathogenesis of CLL

Favorite

4003

VENETOCLAX TREATMENT OF REFRACTORY ITP IN CLL

Clinical Challenges in CLL

Favorite

4004

Tracking CLL cells with mutation in the TP53 gene using scRNAseq in relapsed/refractory patients

Pathogenesis of CLL

Favorite

4005

STop and Restart Acalabrutinib In fRail Patients With Previously Untreated Chronic Lymphocytic Leukemia (STAIR): a randomized phase 2 study from the FILO-CLL group

Therapy of CLL

Favorite

Browse by Poster Number

Browse by Poster Number

193 results found